7 RESULTS
COMMENT There was late snow in Italy that spring. Mount Vesuvius, overlooking the Bay of Naples, was crowned with white, making it look like a child’s drawing of a volcano. A cold wind blew down its slopes and across the water to Sorrento, tempered by the ...
COMMENT We are intrigued by this important technological advance in helping to understand the fate of solutes within the CNS. We previously showed that patients in the first AN1792 Aβ immunotherapy trial (Elan Pharmaceuticals) developed increased severity of ...
COMMENT The interpretation that treatment of patients with the anti-Aβ monoclonal antibody bapineuzumab had an effect on lowering levels of phospho-tau is consistent with our findings in postmortem studies of the brains of patients actively immunized against Aβ ...
COMMENT Is Prevention Better Than Cure? The paper by Sperling and colleagues is a thought-provoking review of where we are presently with respect to Alzheimer's disease therapy, with the emphasis on treating patients earlier in the course of the disease. By ...
COMMENT Our study was a six-year follow-up of patients in the original Elan AN1792 study of active immunization of AD patients with full-length Aβ42 peptide. We have confirmed that Aβ immunization can result in plaque removal from the AD brain. The extent of ...
COMMENT Shin and colleagues have provided very interesting evidence of the physiological dysfunction resulting from CAA in a transgenic mouse model. In humans CAA is usually accompanied by other features of Alzheimer pathology such as plaques and tangles. ...
COMMENT The brain volume changes in patients who were immunized and developed antibodies is interesting, but perhaps not so surprising in retrospect when the information available from the neuropathology is taken into account. You might predict (1) an initial ...
